Back

The efficacy and safety of low-intensity statins for high bleeding risk patients after PCI in Asian populations

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (1) - Dyslipidaemias: current strategies and innovations Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Ze Zhang

Tianjin (China)

9 More presentations in this session

Presentation thumbnail
Discussant - Dyslipidaemias: current strategies and innovations
Presentation thumbnail
Statin users have lower fatty acid oxidative metabolisms in muscle mitochondria and have a higher content of long-chain and medium-chain acylcarnitines in muscles.
Doctor E. Bolsteina (Riga, LV)
Abstract Slides
Presentation thumbnail
The efficacy of tafolecimab in lipoprotein(a) reductions in hypercholesterolaemic patients: a pooled analysis of three phase 3 trials
Ms H. Shen (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Efficacy and metabolic impact of combination therapy vs. high-intensity statin monotherapy: an exploratory analysis of the Save SAMS Trial
Professor S. Hong (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
VICTORION-Mono China: efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated LDL-C
Doctor X. Liu (CH)
Abstract

Access the full session

Session thumbnail
New perspectives in cardiology (1) - Dyslipidaemias: current strategies and innovations

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Pattern of dual antiplatelet use and 12-month outcomes stratified by bleeding and ischemic risk in acute coronary syndrome patients undergoing percutaneous coronary intervention
thumbnail
Congress Presentation
The impact of high-intensity statin on 3-year clinical outcomes in elderly acute myocardial infarction patients underwent percutaneous coronary intervention with drug-eluting stents
thumbnail
Congress Presentation
Association between clinical ischemic risk and thrombogenicity phenotype and their prognostic prediction in patients undergoing percutaneous coronary intervention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources